12 August 2022 - Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld.

That’s the position of multiple patient organisations, clinicians and medical groups, who have criticised the Department of Health’s decision to defer procurement of Evusheld supplies until cost-effectiveness agency NICE has evaluated whether the antibody has durable efficacy against the prevailing Omicron variant of SARS-CoV-2.

Read Pharma Times article